Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Influenza

  Free Subscription


05.04.2021

5 Antimicrob Agents Chemother
2 Antiviral Res
2 BMC Pediatr
2 BMJ
6 Cell
1 Drug Saf
3 Epidemiol Infect
3 J Immunol
2 J Infect Dis
1 J Virol
3 JAMA
12 Lancet
7 N Engl J Med
1 PLoS Med
24 PLoS One
3 Proc Natl Acad Sci U S A
2 Vaccine
2 Virology
2 Virus Res


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Antimicrob Agents Chemother

  1. MAY M, Chang M, Dietz D, Shoucri S, et al
    Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019.
    Antimicrob Agents Chemother. 2021;65.
    PubMed         Abstract available

  2. KUO CJ, Chao TL, Kao HC, Tsai YM, et al
    Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.
    Antimicrob Agents Chemother. 2021;65.
    PubMed         Abstract available

  3. MARTINEZ MA
    Plitidepsin: a repurposed drug for the treatment of COVID-19.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.00200.
    PubMed         Abstract available

  4. GOOD SS, Westover J, Jung KH, Zhou XJ, et al
    AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19.
    Antimicrob Agents Chemother. 2021;65.
    PubMed         Abstract available

  5. MENGUAL-CHULIA B, Alonso-Cordero A, Cano L, Del Mar Mosquera M, et al
    Surveillance of Influenza A resistance to polymerase complex inhibitors by whole genome analysis, 2016-17, 2017-18 and 2018-19 Seasons, Eastern Spain.
    Antimicrob Agents Chemother. 2021 Mar 29. pii: AAC.02718.
    PubMed         Abstract available


    Antiviral Res

  6. MARTIN R, Li J, Parvangada A, Perry J, et al
    Genetic Conservation of SARS-CoV-2 RNA Replication Complex in Globally Circulating Isolates and Recently Emerged Variants from Humans and Minks Suggests Minimal Pre-Existing Resistance to Remdesivir.
    Antiviral Res. 2021 Feb 4:105033. doi: 10.1016/j.antiviral.2021.105033.
    PubMed         Abstract available

  7. BLOCKUS S, Sake SM, Wetzke M, Grethe C, et al
    Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
    Antiviral Res. 2020;177:104774.
    PubMed         Abstract available


    BMC Pediatr

  8. SALEH NY, Aboelghar HM, Salem SS, Ibrahem RA, et al
    The severity and atypical presentations of COVID-19 infection in pediatrics.
    BMC Pediatr. 2021;21:144.
    PubMed         Abstract available

  9. PAUL G, Chad R
    Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination - a case report.
    BMC Pediatr. 2021;21:138.
    PubMed         Abstract available


    BMJ

  10. BHOPAL R, Munro APS
    Scholarly communications harmed by covid-19.
    BMJ. 2021;372:n742.
    PubMed        

  11. PATEL N
    Virtual clinics are reassuring but sometimes daunting.
    BMJ. 2021;372:n622.
    PubMed        


    Cell


  12. Scientific misinformation: A perfect storm, missteps, and moving forward.
    Cell. 2021;184:1402-1406.
    PubMed         Abstract available

  13. SANDRONE S, Scott G, Anderson WJ, Musunuru K, et al
    Active learning-based STEM education for in-person and online learning.
    Cell. 2021;184:1409-1414.
    PubMed         Abstract available

  14. GEITMANN A
    Travel Less. Make It Worthwhile.
    Cell. 2020;182:790-793.
    PubMed         Abstract available

  15. PILLON NJ, Loos RJF, Marshall SM, Zierath JR, et al
    Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care.
    Cell. 2021;184:1530-1544.
    PubMed         Abstract available

  16. TOPOL EJ
    Messenger RNA vaccines against SARS-CoV-2.
    Cell. 2021;184:1401.
    PubMed         Abstract available

  17. GEBRE MS, Brito LA, Tostanoski LH, Edwards DK, et al
    Novel approaches for vaccine development.
    Cell. 2021;184:1589-1603.
    PubMed         Abstract available


    Drug Saf

  18. DASGUPTA N
    Safety Consequences of Off-Label Drugs Used for COVID-19.
    Drug Saf. 2021;44:399-402.
    PubMed        


    Epidemiol Infect

  19. ELSON R, Davies TM, Lake IR, Vivancos R, et al
    The spatio-temporal distribution of COVID-19 infection in England between January and June 2020.
    Epidemiol Infect. 2021;149:e73.
    PubMed         Abstract available

  20. CHENG A, Chen Y, Gao Y, Sun P, et al
    Mobile isolation wards in a fever clinic: a novel operation model during the COVID-19 pandemic.
    Epidemiol Infect. 2021;149:e61.
    PubMed         Abstract available

  21. CASTRO RR, Santos RSC, Sousa GJB, Pinheiro YT, et al
    Spatial dynamics of the COVID-19 pandemic in Brazil.
    Epidemiol Infect. 2021;149:e60.
    PubMed         Abstract available


    J Immunol

  22. FRANZETTI M, Forastieri A, Borsa N, Pandolfo A, et al
    IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study.
    J Immunol. 2021;206:1569-1575.
    PubMed         Abstract available

  23. HUANG W, Li M, Luo G, Wu X, et al
    The Inflammatory Factors Associated with Disease Severity to Predict COVID-19 Progression.
    J Immunol. 2021;206:1597-1608.
    PubMed         Abstract available

  24. RUPP J, Dreo B, Gutl K, Fessler J, et al
    T Cell Phenotyping in Individuals Hospitalized with COVID-19.
    J Immunol. 2021;206:1478-1482.
    PubMed         Abstract available


    J Infect Dis

  25. EATON EF, Clement ME
    Wave the Yellow Flag: Why we should prioritize routine HIV and STI care now.
    J Infect Dis. 2021 Jan 27. pii: 6121541. doi: 10.1093.
    PubMed        

  26. LAMARCA JH, de Carvalho FG, Machado FC, Lacerda-Santos R, et al
    Severe Acute Respiratory Syndrome Coronavirus 2: A Protocol for Disinfection of Toothbrushes.
    J Infect Dis. 2021;223:1113-1114.
    PubMed        


    J Virol

  27. WANG J, Shu T, Deng W, Zheng Y, et al
    Mucosal priming with a recombinant influenza A virus-vectored vaccine elicits T-cell and antibody responses to HIV-1 in mice.
    J Virol. 2021 Mar 31. pii: JVI.00059-21. doi: 10.1128/JVI.00059.
    PubMed         Abstract available


    JAMA

  28. GOSTIN LO
    The Coronavirus Pandemic 1 Year On-What Went Wrong?
    JAMA. 2021;325:1132-1133.
    PubMed        

  29. JANIAUD P, Axfors C, Schmitt AM, Gloy V, et al
    Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    JAMA. 2021 Feb 26. pii: 2777060. doi: 10.1001/jama.2021.2747.
    PubMed         Abstract available

  30. SHARFSTEIN JM, Goodman JL, Borio L
    The US Regulatory System and COVID-19 Vaccines: The Importance of a Strong and Capable FDA.
    JAMA. 2021 Feb 15. pii: 2776658. doi: 10.1001/jama.2021.1961.
    PubMed        


    Lancet

  31. THE LANCET
    COVID-19: building a stronger Europe.
    Lancet. 2021;397:1157.
    PubMed        

  32. MANISTY C, Otter AD, Treibel TA, McKnight A, et al
    Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
    Lancet. 2021 Feb 25. pii: S0140-6736(21)00501.
    PubMed        

  33. BEYRER C, Sullivan P, Adimora AA, Mayer K, et al
    HIV in the USA: priorities for the new administration.
    Lancet. 2020 Nov 27. pii: S0140-6736(20)32524.
    PubMed        

  34. THE LANCET
    Facing up to long COVID.
    Lancet. 2020;396:1861.
    PubMed        

  35. GORNA R, MacDermott N, Rayner C, O'Hara M, et al
    Long COVID guidelines need to reflect lived experience.
    Lancet. 2021;397:455-457.
    PubMed        

  36. FIELDS EL, Copeland R, Hopkins E
    Same script, different viruses: HIV and COVID-19 in US Black communities.
    Lancet. 2021 Feb 18. pii: S0140-6736(20)32522.
    PubMed        

  37. MYLAN S, Hardman C
    COVID-19, cults, and the anti-vax movement.
    Lancet. 2021;397:1181.
    PubMed        


  38. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
    Lancet. 2021 Mar 4. pii: S0140-6736(21)00461.
    PubMed         Abstract available

  39. STEINBERG J, Thomas A, Iravani A
    (18)Fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine.
    Lancet. 2021 Mar 8. pii: S0140-6736(21)00464.
    PubMed        

  40. BOYTON RJ, Altmann DM
    Risk of SARS-CoV-2 reinfection after natural infection.
    Lancet. 2021 Mar 17. pii: S0140-6736(21)00662.
    PubMed        

  41. JAFFE S
    Biden's first legislative victory: $1.9 trillion for COVID-19.
    Lancet. 2021;397:1047-1048.
    PubMed        

  42. HE Z, Ren L, Yang J, Guo L, et al
    Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
    Lancet. 2021;397:1075-1084.
    PubMed         Abstract available


    N Engl J Med

  43. JOYNER MJ, Carter RE, Senefeld JW, Klassen SA, et al
    Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
    N Engl J Med. 2021 Jan 13. doi: 10.1056/NEJMoa2031893.
    PubMed         Abstract available

  44. JAWORSKI JP
    Monoclonal Antibody for Patients with Covid-19.
    N Engl J Med. 2021 Feb 3. pii: 10.1056/NEJMc2100221.
    PubMed        

  45. RUBIN EJ, Baden LR, Brandt AM, Morrissey S, et al
    Audio Interview: What Earlier Epidemics Teach Us about Covid-19.
    N Engl J Med. 2021;384:e55.
    PubMed        

  46. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Efficacy of Current Covid-19 Vaccines against Variant Viruses.
    N Engl J Med. 2021;384:e53.
    PubMed        

  47. KADIRE SR, Fabre V, Wenzel RP
    Doctor, How Long Should I Isolate?
    N Engl J Med. 2021;384:e47.
    PubMed        

  48. ONI-ORISAN A, Mavura Y, Banda Y, Thornton TA, et al
    Embracing Genetic Diversity to Improve Black Health.
    N Engl J Med. 2021;384:1163-1167.
    PubMed        

  49. LUNDGREN JD, Lane HC, Neaton JD
    Monoclonal Antibody for Patients with Covid-19. Reply.
    N Engl J Med. 2021 Feb 3. pii: 10.1056/NEJMc2100221.
    PubMed        


    PLoS Med

  50. LEONG A, Cole JB, Brenner LN, Meigs JB, et al
    Cardiometabolic risk factors for COVID-19 susceptibility and severity: A Mendelian randomization analysis.
    PLoS Med. 2021;18:e1003553.
    PubMed         Abstract available


    PLoS One

  51. MARIN-GOMEZ FX, Fabregas-Escurriola M, Segui FL, Perez EH, et al
    Assessing the likelihood of contracting COVID-19 disease based on a predictive tree model: A retrospective cohort study.
    PLoS One. 2021;16:e0247995.
    PubMed         Abstract available

  52. LAWSON AB, Kim J
    Space-time covid-19 Bayesian SIR modeling in South Carolina.
    PLoS One. 2021;16:e0242777.
    PubMed         Abstract available

  53. CHUKWUDOZIE OS, Gray CM, Fagbayi TA, Chukwuanukwu RC, et al
    Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein.
    PLoS One. 2021;16:e0248061.
    PubMed         Abstract available

  54. CRUZ-GONZALEZ A, Munoz-Velasco I, Cottom-Salas W, Becerra A, et al
    Structural analysis of viral ExoN domains reveals polyphyletic hijacking events.
    PLoS One. 2021;16:e0246981.
    PubMed         Abstract available

  55. HASSAN EM, Mahmoud HN
    Impact of multiple waves of COVID-19 on healthcare networks in the United States.
    PLoS One. 2021;16:e0247463.
    PubMed         Abstract available

  56. CURTIS RG, Olds T, Ferguson T, Fraysse F, et al
    Changes in diet, activity, weight, and wellbeing of parents during COVID-19 lockdown.
    PLoS One. 2021;16:e0248008.
    PubMed         Abstract available

  57. STERR CM, Nickel IL, Stranzinger C, Nonnenmacher-Winter CI, et al
    Medical face masks offer self-protection against aerosols: An evaluation using a practical in vitro approach on a dummy head.
    PLoS One. 2021;16:e0248099.
    PubMed         Abstract available

  58. KOEHLER D, Ozga AK, Molwitz I, May P, et al
    Time series analysis of the demand for COVID-19 related chest imaging during the first wave of the SARS-CoV-2 pandemic: An explorative study.
    PLoS One. 2021;16:e0247686.
    PubMed         Abstract available

  59. ALKURT G, Murt A, Aydin Z, Tatli O, et al
    Seroprevalence of coronavirus disease 2019 (COVID-19) among health care workers from three pandemic hospitals of Turkey.
    PLoS One. 2021;16:e0247865.
    PubMed         Abstract available

  60. PORCHER S, Renault T
    Social distancing beliefs and human mobility: Evidence from Twitter.
    PLoS One. 2021;16:e0246949.
    PubMed         Abstract available

  61. GERMANI F, Biller-Andorno N
    The anti-vaccination infodemic on social media: A behavioral analysis.
    PLoS One. 2021;16:e0247642.
    PubMed         Abstract available

  62. LINARES L, Cofan F, Diekmann F, Herrera S, et al
    A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients.
    PLoS One. 2021;16:e0247251.
    PubMed         Abstract available

  63. JANG WS, Lim DH, Yoon J, Kim A, et al
    Development of a multiplex Loop-Mediated Isothermal Amplification (LAMP) assay for on-site diagnosis of SARS CoV-2.
    PLoS One. 2021;16:e0248042.
    PubMed         Abstract available

  64. CUGMAS M, Ferligoj A, Kogovsek T, Batagelj Z, et al
    The social support networks of elderly people in Slovenia during the Covid-19 pandemic.
    PLoS One. 2021;16:e0247993.
    PubMed         Abstract available

  65. WEISS JJ, Attuquayefio TN, White EB, Li F, et al
    Tracking smell loss to identify healthcare workers with SARS-CoV-2 infection.
    PLoS One. 2021;16:e0248025.
    PubMed         Abstract available

  66. LOCATELLI I, Trachsel B, Rousson V
    Estimating the basic reproduction number for COVID-19 in Western Europe.
    PLoS One. 2021;16:e0248731.
    PubMed         Abstract available

  67. NAGASU M, Muto K, Yamamoto I
    Impacts of anxiety and socioeconomic factors on mental health in the early phases of the COVID-19 pandemic in the general population in Japan: A web-based survey.
    PLoS One. 2021;16:e0247705.
    PubMed         Abstract available

  68. KOENEN M, Balvert M, Brekelmans R, Fleuren H, et al
    Forecasting the spread of SARS-CoV-2 is inherently ambiguous given the current state of virus research.
    PLoS One. 2021;16:e0245519.
    PubMed         Abstract available

  69. ANWARI V, Ng WCK, Mbadjeu Hondjeu AR, Xiao Z, et al
    Development, manufacturing, and preliminary validation of a reusable half-face respirator during the COVID-19 pandemic.
    PLoS One. 2021;16:e0247575.
    PubMed         Abstract available

  70. TEMPSKI P, Arantes-Costa FM, Kobayasi R, Siqueira MAM, et al
    Medical students' perceptions and motivations during the COVID-19 pandemic.
    PLoS One. 2021;16:e0248627.
    PubMed         Abstract available

  71. STEWART M, Rodriguez-Watson C, Albayrak A, Asubonteng J, et al
    COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients.
    PLoS One. 2021;16:e0248128.
    PubMed         Abstract available

  72. VICENS P, Heredia L, Bustamante E, Perez Y, et al
    Does living close to a petrochemical complex increase the adverse psychological effects of the COVID-19 lockdown?
    PLoS One. 2021;16:e0249058.
    PubMed         Abstract available

  73. LAHMER T, Kriescher S, Herner A, Rothe K, et al
    Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: Results from the prospective AspCOVID-19 study.
    PLoS One. 2021;16:e0238825.
    PubMed         Abstract available

  74. BERGER LM, Ferrari G, Leturcq M, Panico L, et al
    COVID-19 lockdowns and demographically-relevant Google Trends: A cross-national analysis.
    PLoS One. 2021;16:e0248072.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  75. KORN L, Bohm R, Betsch C
    Reply to Rabb et al.: Why promoting COVID-19 vaccines with community immunity is not a good strategy (yet).
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed        

  76. SNEPPEN K, Nielsen BF, Taylor RJ, Simonsen L, et al
    Overdispersion in COVID-19 increases the effectiveness of limiting nonrepetitive contacts for transmission control.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available

  77. HONG B, Bonczak BJ, Gupta A, Thorpe LE, et al
    Exposure density and neighborhood disparities in COVID-19 infection risk.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available


    Vaccine

  78. GUR-ARIE R, Katz MA, Hirsch A, Greenberg D, et al
    "You Have to Die Not to Come to Work": A Mixed Methods Study of Attitudes and Behaviors regarding Presenteeism, Absenteeism and Influenza Vaccination among Healthcare Personnel with Respiratory Illness in Israel, 2016-2019.
    Vaccine. 2021 Mar 29. pii: S0264-410X(21)00361.
    PubMed         Abstract available

  79. GKENTZI D, Aggelopoulos K, Karatza A, Sinopidis X, et al
    Influenza vaccination among caregivers and household contacts of children with asthma.
    Vaccine. 2021 Mar 25. pii: S0264-410X(21)00325.
    PubMed         Abstract available


    Virology

  80. CASE JB, Winkler ES, Errico JM, Diamond MS, et al
    On the road to ending the COVID-19 pandemic: Are we there yet?
    Virology. 2021;557:70-85.
    PubMed         Abstract available

  81. DJUKIC T, Mladenovic M, Stanic-Vucinic D, Radosavljevic J, et al
    Expression, purification and immunological characterization of recombinant nucleocapsid protein fragment from SARS-CoV-2.
    Virology. 2021;557:15-22.
    PubMed         Abstract available


    Virus Res

  82. MIRANDA RL, Guterres A, de Azeredo Lima CH, Filho PN, et al
    Misinterpretation of viral load in COVID-19 clinical outcomes.
    Virus Res. 2021;296:198340.
    PubMed         Abstract available

  83. FRANCISCO RDS JR, Benites LF, Lamarca AP, de Almeida LGP, et al
    Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil.
    Virus Res. 2021;296:198345.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: